Eloxx Pharmaceuticals Inc

NASDAQ:ELOX  
1.32
-0.05 (-3.65%)
Regulatory, Other Pre-Announcement

Eloxx Pharmaceuticals Provides Enrollment Update For Ongoing Phase 2 Clinical Studies For Cystic Fibrosis

Published: 07/06/2021 20:23 GMT
Eloxx Pharmaceuticals Inc (ELOX) - Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis.
Eloxx Pharmaceuticals Inc - Based on Enrollment to Date, Eloxx Expects to Present Data From First Four Treatment Arms of Study in Q4 of This Year.
Eloxx Pharmaceuticals Inc - Eloxx Will Continue to Enroll Additional Patients to Support Phase 3 Clinical Trial Planning.